{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:19:21Z","timestamp":1780582761442,"version":"3.54.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Misr International University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Coronavirus Disease 2019 (COVID-19) continues to spread rapidly. Monoclonal antibodies as well as anti-tumor necrosis factor are considered promising treatments for COVID-19. A prospective cohort study in which patients are divided into three groups. Group 1: moderate and severe COVID-19 patients received standard treatment; Group 2: moderate and severe COVID-19 patients received tocilizumab; Group 3: moderate and severe COVID-19 patients received treatment with infliximab and tocilizumab. 153 patients were recruited in the study. 40 received standard treatment alone, 70 received tocilizumab with standard treatment, and 43 received tocilizumab\/infliximab with standard treatment. There was a significant difference in length of hospital stay (10.3, 8.9, and 7.6\u00a0days respectively <jats:italic>P<\/jats:italic>\u2009=\u20090.03), need for a non-invasive mechanical ventilator (4, 5, and one patient; <jats:italic>P<\/jats:italic>\u2009=\u20091.2E\u22128), intensive care admission (32, 45, and 16 patients; <jats:italic>P<\/jats:italic>\u2009=\u20092.5E\u22125), the occurrence of sepsis (18, 12, and 10 patients; <jats:italic>P<\/jats:italic>\u2009=\u20090.005) and in death (42.5%, 14.2%, and 7%; <jats:italic>P<\/jats:italic>\u2009=\u20090.0008) which were significantly lower in tocilizumab\/infliximab group compared to tocilizumab and standard of care groups. Our study showed that tocilizumab\/ infliximab in addition to standard of care was considered a promising treatment for moderate and severe COVID-19 patients.<\/jats:p><jats:p>Trial registration number: ClinicalTrials.gov NCT04734678; date of registration: 02\/02\/2021.<\/jats:p>","DOI":"10.1038\/s41598-023-33484-6","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T14:31:39Z","timestamp":1682001099000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Evaluation of infliximab\/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4067-5518","authenticated-orcid":false,"given":"Neven Mohamed","family":"Sarhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Essam Abou","family":"Warda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haytham Soliman Ghareeb","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona Farag","family":"Schaalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaimaa Mohamed","family":"Fathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"issue":"8","key":"33484_CR1","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1001\/jama.2020.12839","volume":"324","author":"WJ Wiersinga","year":"2020","unstructured":"Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J. & Prescott, H. C. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA 324(8), 782\u2013793 (2020).","journal-title":"JAMA"},{"key":"33484_CR2","unstructured":"Johns Hopkins. COVID-19 Dashboard by the Center for Science and Engineering. 2021. https:\/\/coronavirus.jhu.edu\/map.html. Accessed 14 December 2021."},{"key":"33484_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2020.115327","author":"S Kaur","year":"2020","unstructured":"Kaur, S., Bansal, Y., Kumar, R. & Bansal, G. A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors. Bioorgan. Med. Chem. https:\/\/doi.org\/10.1016\/j.bmc.2020.115327 (2020).","journal-title":"Bioorgan. Med. Chem."},{"issue":"8","key":"33484_CR4","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","volume":"23","author":"RQ Le","year":"2018","unstructured":"Le, R. Q. et al. FDA approval summary: Tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life- threatening cytokine release syndrome. Oncologist 23(8), 943\u2013947. https:\/\/doi.org\/10.1634\/theoncologist.2018-0028 (2018).","journal-title":"Oncologist"},{"issue":"2","key":"33484_CR5","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124(2), 188\u2013195. https:\/\/doi.org\/10.1182\/blood-2014-05-552729 (2014).","journal-title":"Blood"},{"issue":"10223","key":"33484_CR6","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223), 497\u2013506. https:\/\/doi.org\/10.1016\/S0140-6736(20)30183-5 (2020) (Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 30;: PMID: 31986264).","journal-title":"Lancet"},{"key":"33484_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-05991-x","author":"Q Ruan","year":"2020","unstructured":"Ruan, Q., Yang, K., Wang, W., Jiang, L. & Song, J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. https:\/\/doi.org\/10.1007\/s00134-020-05991-x (2020).","journal-title":"Intensive Care Med."},{"key":"33484_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102452","author":"B Liu","year":"2020","unstructured":"Liu, B., Li, M., Zhou, Z., Guan, X. & Xiang, Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?. J. Autoimmun. https:\/\/doi.org\/10.1016\/j.jaut.2020.102452 (2020).","journal-title":"J. Autoimmun."},{"issue":"7","key":"33484_CR9","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1136\/gutjnl-2020-321269","volume":"69","author":"MF Neurath","year":"2020","unstructured":"Neurath, M. F. Covid-19 and immunomodulation in IBD. Gut 69(7), 1335\u20131342. https:\/\/doi.org\/10.1136\/gutjnl-2020-321269 (2020).","journal-title":"Gut"},{"issue":"1000-Genomes","key":"33484_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13054-020-02960-0","volume":"24","author":"G Riva","year":"2020","unstructured":"Riva, G., Nasillo, V., Tagliafico, E., Trenti, T. & Luppi, M. COVID-19: Room for treating T cell exhaustion?. Crit. Care 24(1000-Genomes), 1\u20132. https:\/\/doi.org\/10.1186\/s13054-020-02960-0 (2020).","journal-title":"Crit. Care"},{"key":"33484_CR11","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.gastro.2020.05.032","volume":"159","author":"EJ Brenner","year":"2020","unstructured":"Brenner, E. J. et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: Results from an international registry. Gastroenterology 159, 481-491.e3 (2020).","journal-title":"Gastroenterology"},{"key":"33484_CR12","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","volume":"584","author":"EJ Williamson","year":"2020","unstructured":"Williamson, E. J. et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 584, 430\u2013436 (2020).","journal-title":"Nature"},{"issue":"12","key":"33484_CR13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2023616","volume":"383","author":"LE Egede","year":"2020","unstructured":"Egede, L. E. & Walker, R. J. Structural racism, social risk factors, and Covid-19\u2014A dangerous convergence for Black Americans. N. Engl. J. Med. 383(12), e77 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"33484_CR14","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.chom.2020.04.009","volume":"27","author":"EJ Giamarellos-Bourboulis","year":"2020","unstructured":"Giamarellos-Bourboulis, E. J. et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe 27(6), 992-1000.e3 (2020).","journal-title":"Cell Host Microbe"},{"key":"33484_CR15","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta, P. et al. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 395, 1033\u20131034 (2020).","journal-title":"Lancet"},{"key":"33484_CR16","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1002\/jmv.25948","volume":"92","author":"M Aziz","year":"2020","unstructured":"Aziz, M., Fatima, R. & Assaly, R. Elevated interleukin-6 and severe COVID-19: A meta- analysis. J. Med. Virol. 92, 2283\u20132285 (2020).","journal-title":"J. Med. Virol."},{"issue":"1","key":"33484_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/jmv.26085","volume":"93","author":"J Zhu","year":"2020","unstructured":"Zhu, J. et al. Elevated interleukin- 6 is associated with severity of COVID-19: A meta-analysis. J. Med. Virol. 93(1), 35 (2020).","journal-title":"J. Med. Virol."},{"issue":"10","key":"33484_CR18","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jaci.2020.05.008","volume":"146","author":"T Herold","year":"2020","unstructured":"Herold, T. et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J. Allergy Clin. Immunol. 146(10), 128-136.e4 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"33484_CR19","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S0140-6736(20)30858-8","volume":"395","author":"M Feldmann","year":"2020","unstructured":"Feldmann, M. et al. Trials ofanti-tumour necrosis factor therapy for COVID19 are urgently needed. Lancet 395, 1407\u20131409 (2020).","journal-title":"Lancet"},{"key":"33484_CR20","first-page":"E653","volume":"2","author":"PC Robinson","year":"2020","unstructured":"Robinson, P. C., Richards, D., Tanner, H. L. & Feldmann, M. Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment. LancetRheumatol. 2, E653\u2013E655 (2020).","journal-title":"LancetRheumatol."},{"key":"33484_CR21","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","volume":"26","author":"DM Del Valle","year":"2020","unstructured":"Del Valle, D. M. et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 26, 1636\u20131643 (2020).","journal-title":"Nat. Med."},{"key":"33484_CR22","unstructured":"Actemra prescribing information. South San Francisco, CA: Genentech, 2019 (package insert)."},{"key":"33484_CR23","unstructured":"RoActemra summary of product characteristics. Grenzach-Wyhlen, Germany: Roche, 2020."},{"key":"33484_CR24","unstructured":"Roche. Roche provides an update on the phase III COVACTA trial of Actemra\/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia. July 29, 2020. https:\/\/www.roche.com\/investors\/updates\/inv-update-2020-07-29.htm."},{"key":"33484_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102512","volume":"114","author":"AR Morrison","year":"2020","unstructured":"Morrison, A. R. et al. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab. J. Autoimmun. 114, 102512 (2020).","journal-title":"J. Autoimmun."},{"issue":"1","key":"33484_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","volume":"181","author":"O Hermine","year":"2020","unstructured":"Hermine, O. et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Intern. Med. 181(1), 32\u201340 (2020).","journal-title":"JAMA Intern. Med."},{"key":"33484_CR27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028836","author":"JH Stone","year":"2020","unstructured":"Stone, J. H. et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2028836 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"1000-Genomes","key":"33484_CR28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2030340","volume":"384","author":"C Salama","year":"2021","unstructured":"Salama, C. et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N. Engl. J. Med. 384(1000-Genomes), 20\u201330 (2021).","journal-title":"N. Engl. J. Med."},{"key":"33484_CR29","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1186\/s13054-020-03158-0","volume":"24","author":"A Stallmach","year":"2020","unstructured":"Stallmach, A. et al. Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series. Crit. Care 24, 444 (2020).","journal-title":"Crit. Care"},{"issue":"1000-Genomes","key":"33484_CR30","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S2468-1253(20)30269-7","volume":"5","author":"EJ Brenner","year":"2020","unstructured":"Brenner, E. J., Ungaro, R. C., Colombel, J. F. & Kappelman, M. D. IBD in the COVID-19 era: The value of international collaboration. Lancet Gastroenterol. Hepatol. 5(1000-Genomes), 887\u2013888. https:\/\/doi.org\/10.1016\/S2468-1253(20)30269-7 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"33484_CR31","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1053\/j.gastro.2020.04.043","volume":"159","author":"I Rodr\u00edguez-Lago","year":"2020","unstructured":"Rodr\u00edguez-Lago, I. et al. Characteristics and prognosis of patients with inflammatory bowel disease during the SARS-CoV-2 pandemic in the Basque country (Spain). Gastroenterology 159, 781\u2013783 (2020).","journal-title":"Gastroenterology"},{"key":"33484_CR32","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/apt.15897","volume":"52","author":"CH Waggershauser","year":"2020","unstructured":"Waggershauser, C. H. et al. Letter: immunotherapy in IBD patients in a SARS-CoV2 endemic area. Aliment. Pharmacol. Ther. 52, 898\u2013899 (2020).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"33484_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis2020-218580","author":"KL Winthrop","year":"2020","unstructured":"Winthrop, K. L. et al. SARS CoV-2 infection among patients using immunomodulatory therapies. Ann. Rheum. Dis. https:\/\/doi.org\/10.1136\/annrheumdis2020-218580 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"33484_CR34","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1001\/jama.1995.03520360048038","volume":"273","author":"E Abraham","year":"1995","unstructured":"Abraham, E. et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor a in patients with sepsis syndrome. A randomized, controlled, doubleblind, multicenter clinical trial.TNF-a MAb Sepsis Study Group. JAMA 273, 934\u2013941 (1995).","journal-title":"JAMA"},{"key":"33484_CR35","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1097\/00003246-199609000-00002","volume":"24","author":"J Cohen","year":"1996","unstructured":"Cohen, J., Carlet, J., International Sepsis Trial Study Group. INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. Crit. Care Med. 24, 1431\u20131440 (1996).","journal-title":"Crit. Care Med."},{"issue":"1000-Genomes","key":"33484_CR36","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1017\/cts.2021.805","volume":"5","author":"H Hachem","year":"2021","unstructured":"Hachem, H. et al. Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNF\u03b1-antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure. J. Clin. Transl. Sci. 5(1000-Genomes), e146. https:\/\/doi.org\/10.1017\/cts.2021.805 (2021) (PMID: 34457357).","journal-title":"J. Clin. Transl. Sci."},{"issue":"4","key":"33484_CR37","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.jinf.2020.06.053","volume":"81","author":"Z Lin","year":"2020","unstructured":"Lin, Z. et al. Serum ferritin as an independent risk factor for severity in COVID-19 patients. J. Infect. 81(4), 647\u2013679. https:\/\/doi.org\/10.1016\/j.jinf.2020.06.053 (2020) (Epub 2020 Jun 24 PMID: 32592705).","journal-title":"J. Infect."},{"issue":"7","key":"33484_CR38","doi-asserted-by":"publisher","first-page":"e12421","DOI":"10.15252\/emmm.202012421","volume":"12","author":"T Liu","year":"2020","unstructured":"Liu, T. et al. The role of interleukin-6 in monitoring the severe case of coronavirus disease 2019. EMBO Mol. Med. 12(7), e12421 (2020).","journal-title":"EMBO Mol. Med."},{"key":"33484_CR39","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1002\/jmv.26062","volume":"92","author":"M Benucci","year":"2020","unstructured":"Benucci, M. et al. COVID-19 pneumonia treated with sarilumab: A clinical series of eight patients. J. Med. Virol. 92, 2368 (2020).","journal-title":"J. Med. Virol."},{"issue":"10","key":"33484_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30313-1","volume":"2","author":"B Furlow","year":"2020","unstructured":"Furlow, B. COVACTA trial raises questions about tocilizumab\u2019s benefit in COVID-19. Lancet Rheumatol. 2(10), e592 (2020).","journal-title":"Lancet Rheumatol."},{"key":"33484_CR41","doi-asserted-by":"crossref","unstructured":"Chousterman, B. G., Swirski, F. K., & Weber, G. F. (2017). Cytokine storm and sepsis disease pathogenesis. In Seminars in Immunopathology (Vol. 39, pp. 517\u2013528).","DOI":"10.1007\/s00281-017-0639-8"},{"issue":"2","key":"33484_CR42","first-page":"188","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood J. Am. Soc. Hematol. 124(2), 188\u2013195 (2014).","journal-title":"Blood J. Am. Soc. Hematol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33484-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33484-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33484-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T15:11:04Z","timestamp":1682003464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33484-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["33484"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-33484-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]},"assertion":[{"value":"9 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6456"}}